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Background
In Canada and the US, omalizumab is indicated for
adults and adolescents (>12 years of age) with moderate
to severe persistent allergic asthma. In the EU, omalizu-
mab has been approved for children (age 6 – 11 years)
since 2009. The pediatric population within Canada and
the United States has very few treatment options avail-
able for severe asthma. Current treatments options can
lead to other health concerns such as adrenal insuffi-
ciency and osteoporosis. These cases demonstrate that
early treatment of moderate to severe asthma with oma-
lizumab is an effective treatment and can help to pre-
vent or reverse damage done by long-term use of other
treatment options.
Methods
A retrospective chart review of our database was per-
formed and patients ≤ 17 years of age receiving omalizu-
mab treatment were evaluated. Data was collected on
FEV1, inhaled corticosteroid (ICS) and oral corticosteroid
(OCS) use.
Results
12 patients were identified as 17 years old or younger at
the start of treatment with omalizumab. After the first
6 months of treatment, all 12 patients showed an increase
in FEV1 results and a decrease in ICS dose. Results also
indicated a decrease in OCS use for those patients taking
daily dose as well as those who required periodic bursts
to control asthma exacerbations.
Conclusion
Early treatment of moderate to severe asthma with omali-
zumab in adolescent/pediatric patients may improve qual-
ity of life and help prevent health concerns associated with
side effects and/or long term use of ICS and OCS in grow-
ing children. Juvenile osteoporosis can be a significant pro-
blem because it occurs during the prime bone-building
years and may lead to reduced peak bone mass and
increased risk for osteoporosis later in life. Regular re-
evaluation of the treatment regime to ensure the use of
the lowest effective dose of corticosteroids and consid-
eration of other treatments would also be beneficial.
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